[Pulmonary hypertension].
Olschewski
H
H
Medizinische Klinik und Poliklinik II, Universitätsklinikum Giessen. Horst.Olschewski@innere.med.uni-giessen.de
Ghofrani
A
A
Wiedemann
R
R
Rose
F
F
Enke
B
B
Gessler
T
T
Voswinckel
R
R
Kohstall
M
M
Grimminger
F
F
Seeger
W
W
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D011464:Epoprostenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D065128:Endothelin Receptor Antagonists; D014665:Vasodilator Agents; D011464:Epoprostenol